OncLive’s State of the Science Summit Will Highlight Ovarian Cancer Treatments

OncLive’s State of the Science Summit Will Highlight Ovarian Cancer Treatments
This post was originally published on this site

OncLive’s latest State of the Science Summit will feature discussions of novel treatments for ovarian cancer and soft tissue sarcoma (STS), with presenters from the Dana-Farber Cancer Institute.

To be held Dec. 11 in Boston, Massachusetts at The Colonnade Boston Hotel, the interactive and educational meeting will be chaired by Joyce Fu Liu, the institute’s director of clinical research, division of gynecologic oncology. She’s also an assistant professor of medicine at Harvard Medical School.

Go here to register for the free event, or contact Kayla Collins at [email protected] A new podcast, OncLive On Air, will feature interviews with faculty conducted at this and other summits.

The Boston meeting targets community oncologists interested in the treatment of ovarian cancer and STS patients. Academic fellows, nurse practitioners, researchers, and other healthcare professionals are also invited.

In addition to delving into topics facing ovarian cancer specialists and related professionals, presenters will discuss issues such as surgical options in newly diagnosed ovarian cancer, newly diagnosed advanced ovarian cancer, genetic testing in ovarian cancer, systemic treatment of STS or uterine leiomyosarcoma, treatment of recurrent ovarian cancer, PARP inhibitors for recurrent ovarian cancer, maintenance and relapsed disease, and immunotherapy for gynecologic cancers.

There will also be a panel discussion on somatic testing, a peer-exchange discussion, and an opportunity for audience questions, according to a news release.

Institute presenters will include Susana M. Campos, physician and assistant professor of medicine, Harvard; Suzanne George, director of clinical research, Center for Sarcoma and Bone Oncology, senior physician, associate professor of medicine, Harvard; Neil Horowitz, director of clinical research in gynecologic oncology, associate professor of medicine, Harvard; and Panagiotis A. Konstantinopoulos, director of translational research, gynecologic oncology, physician, associate professor of medicine, Harvard.

They also include Ursula A. Matulonis, physician, chief, division of gynecologic oncology, Susan F. Smith Center for Women’s Cancers, professor of medicine, Harvard; and Huma Q. Rana, clinical director, cancer genetics and prevention, physician, instructor in medicine, Harvard.

The summit series assembles cross-discipline academic and community-based physicians and healthcare professionals from medical and surgical oncology. Specialist experts serve as faculty for these events, which focus on cutting-edge cancer topics aimed at improving patient care.

Summits are held in various locations throughout the country. Go here to find a host city or to sort by cancer type.

About 21,000 women in the United States are diagnosed annually with ovarian cancer, a malignancy that begins in egg-production organs. STS is a rare cancer that begins in the tissues that connect, support and surround other body structures.

OncLive is a digital platform of resources for practicing oncologists, who can use the information to better care for patients.

The post OncLive’s State of the Science Summit Will Highlight Ovarian Cancer Treatments appeared first on Ovarian Cancer News Today.

Chris Comish serves as the Publisher of the website, and is responsible for directing the editorial focus as well as putting the finishing touches on many featured articles.